The development of the EULAR–OMERACT rheumatoid arthritis MRI reference image atlas

Based on a previously developed rheumatoid arthritis MRI scoring system (OMERACT 2002 RAMRIS), the development team agreed which joints, MRI features, MRI sequences, and image planes would best illustrate the scoring system in an atlas. After collecting representative examples for all grades for each abnormality (synovitis, bone oedema, and bone erosion), the team met for a three day period to review the images and choose by consensus the most illustrative set for each feature, site, and grade. A predefined subset of images (for example, for erosion—all coronal slices through the bone) was extracted. These images were then re-read by the group at a different time point to confirm the scores originally assigned. Finally, all selected images were photographed and formatted by one centre and distributed to all readers for final approval

The Magnetic Field of the Solar Corona from Pulsar Observations

We present a novel experiment with the capacity to independently measure both the electron density and the magnetic field of the solar corona. We achieve this through measurement of the excess Faraday rotation due to propagation of the polarised emission from a number of pulsars through the magnetic field of the solar corona. This method yields independent measures of the integrated electron density, via dispersion of the pulsed signal and the magnetic field, via the amount of Faraday rotation. In principle this allows the determination of the integrated magnetic field through the solar corona along many lines of sight without any assumptions regarding the electron density distribution. We present a detection of an increase in the rotation measure of the pulsar J1801$-$2304 of approximately 160 \rad at an elongation of 0.95$^\circ$ from the centre of the solar disk. This corresponds to a lower limit of the magnetic field strength along this line of sight of $> 393\mu\mathrm{G}$. The lack of precision in the integrated electron density measurement restricts this result to a limit, but application of coronal plasma models can further constrain this to approximately 20mG, along a path passing 2.5 solar radii from the solar limb. Which is consistent with predictions obtained using extensions to the Source Surface models published by Wilcox Solar ObservatoryComment: 16 pages, 4 figures (1 colour): Submitted to Solar Physic

Initial State Interactions for K−K^--Proton Radiative Capture

The effects of the initial state interactions on the $K^--p$ radiative capture branching ratios are examined and found to be quite sizable. A general coupled-channel formalism for both strong and electromagnetic channels using a particle basis is presented, and applied to all the low energy $K^--p$ data with the exception of the {\it 1s} atomic level shift. Satisfactory fits are obtained using vertex coupling constants for the electromagnetic channels that are close to their expected SU(3) values.Comment: 16 pages, uses revte

Cosmological bounds on large extra dimensions from non-thermal production of Kaluza-Klein modes

The existing cosmological constraints on theories with large extra dimensions rely on the thermal production of the Kaluza-Klein modes of gravitons and radions in the early Universe. Successful inflation and reheating, as well as baryogenesis, typically requires the existence of a TeV-scale field in the bulk, most notably the inflaton. The non-thermal production of KK modes with masses of order 100 GeV accompanying the inflaton decay sets the lower bounds on the fundamental scale M_*. For a 1 TeV inflaton, the late decay of these modes distort the successful predictions of Big Bang Nucleosynthesis unless M_*> 35, 13, 7, 5 and 3 TeV for 2, 3, 4, 5 and 6 extra dimensions, respectively. This improves the existing bounds from cosmology on M_* for 4, 5 and 6 extra dimensions. Even more stringent bounds are derived for a heavier inflaton.Comment: 17 pages, latex, 4 figure

Multiple recombination events between two cytochrome P450 loci contribute to global pyrethroid resistance in Helicoverpa armigera

The cotton bollworm, Helicoverpa armigera (Hübner) is one of the most serious insect pest species to evolve resistance against many insecticides from different chemical classes. This species has evolved resistance to the pyrethroid insecticides across its native range and is becoming a truly global pest after establishing in South America and having been recently recorded in North America. A chimeric cytochrome P450 gene, CYP337B3, has been identified as a resistance mechanism for resistance to fenvalerate and cypermethrin. Here we show that this resistance mechanism is common around the world with at least eight different alleles. It is present in South America and has probably introgressed into its closely related native sibling species, Helicoverpa zea. The different alleles of CYP337B3 are likely to have arisen independently in different geographic locations from selection on existing diversity. The alleles found in Brazil are those most commonly found in Asia, suggesting a potential origin for the incursion of H. armigera into the Americas

Some ideas about quantitative convergence of collision models to their mean field limit

We consider a stochastic $N$-particle model for the spatially homogeneous Boltzmann evolution and prove its convergence to the associated Boltzmann equation when $N\to \infty$. For any time $T>0$ we bound the distance between the empirical measure of the particle system and the measure given by the Boltzmann evolution in some homogeneous negative Sobolev space. The control we get is Gaussian, i.e. we prove that the distance is bigger than $x N^{-1/2}$ with a probability of type $O(e^{-x^2})$. The two main ingredients are first a control of fluctuations due to the discrete nature of collisions, secondly a Lipschitz continuity for the Boltzmann collision kernel. The latter condition, in our present setting, is only satisfied for Maxwellian models. Numerical computations tend to show that our results are useful in practice.Comment: 27 pages, references added and style improve

First Measurement of Z/gamma* Production in Compton Scattering of Quasi-real Photons

We report the first observation of Z/gamma* production in Compton scattering of quasi-real photons. This is a subprocess of the reaction e+e- to e+e-Z/gamma*, where one of the final state electrons is undetected. Approximately 55 pb-1 of data collected in the year 1997 at an e+e- centre-of-mass energy of 183 GeV with the OPAL detector at LEP have been analysed. The Z/gamma* from Compton scattering has been detected in the hadronic decay channel. Within well defined kinematic bounds, we measure the product of cross-section and Z/gamma* branching ratio to hadrons to be (0.9+-0.3+-0.1) pb for events with a hadronic mass larger than 60 GeV, dominated by (e)eZ production. In the hadronic mass region between 5 GeV and 60 GeV, dominated by (e)egamma* production, this product is found to be (4.1+-1.6+-0.6) pb. Our results agree with the predictions of two Monte Carlo event generators, grc4f and PYTHIA.Comment: 18 pages, LaTeX, 5 eps figures included, submitted to Physics Letters

Search for Higgs Bosons in e+e- Collisions at 183 GeV

The data collected by the OPAL experiment at sqrts=183 GeV were used to search for Higgs bosons which are predicted by the Standard Model and various extensions, such as general models with two Higgs field doublets and the Minimal Supersymmetric Standard Model (MSSM). The data correspond to an integrated luminosity of approximately 54pb-1. None of the searches for neutral and charged Higgs bosons have revealed an excess of events beyond the expected background. This negative outcome, in combination with similar results from searches at lower energies, leads to new limits for the Higgs boson masses and other model parameters. In particular, the 95% confidence level lower limit for the mass of the Standard Model Higgs boson is 88.3 GeV. Charged Higgs bosons can be excluded for masses up to 59.5 GeV. In the MSSM, mh > 70.5 GeV and mA > 72.0 GeV are obtained for tan{beta}>1, no and maximal scalar top mixing and soft SUSY-breaking masses of 1 TeV. The range 0.8 < tanb < 1.9 is excluded for minimal scalar top mixing and m{top} < 175 GeV. More general scans of the MSSM parameter space are also considered.Comment: 49 pages. LaTeX, including 33 eps figures, submitted to European Physical Journal

A Measurement of the Product Branching Ratio f(b->Lambda_b).BR(Lambda_b->Lambda X) in Z0 Decays

The product branching ratio, f(b->Lambda_b).BR(Lambda_b->Lambda X), where Lambda_b denotes any weakly-decaying b-baryon, has been measured using the OPAL detector at LEP. Lambda_b are selected by the presence of energetic Lambda particles in bottom events tagged by the presence of displaced secondary vertices. A fit to the momenta of the Lambda particles separates signal from B meson and fragmentation backgrounds. The measured product branching ratio is f(b->Lambda_b).BR(Lambda_b->Lambda X) = (2.67+-0.38(stat)+0.67-0.60(sys))% Combined with a previous OPAL measurement, one obtains f(b->Lambda_b).BR(Lambda_b->Lambda X) = (3.50+-0.32(stat)+-0.35(sys))%.Comment: 16 pages, LaTeX, 3 eps figs included, submitted to the European Physical Journal

Ivermectin, ‘Wonder drug’ from Japan: the human use perspective

Discovered in the late-1970s, the pioneering drug ivermectin, a dihydro derivative of avermectin—originating solely from a single microorganism isolated at the Kitasato Intitute, Tokyo, Japan from Japanese soil—has had an immeasurably beneficial impact in improving the lives and welfare of billions of people throughout the world. Originally introduced as a veterinary drug, it kills a wide range of internal and external parasites in commercial livestock and companion animals. It was quickly discovered to be ideal in combating two of the world’s most devastating and disfiguring diseases which have plagued the world’s poor throughout the tropics for centuries. It is now being used free-of-charge as the sole tool in campaigns to eliminate both diseases globally. It has also been used to successfully overcome several other human diseases and new uses for it are continually being found. This paper looks in depth at the events surrounding ivermectin’s passage from being a huge success in Animal Health into its widespread use in humans, a development which has led many to describe it as a “wonder” drug